Sign in Sign up for free

Last updated: 23 July 2019 at 7:58am EST

Mark B Skaletsky Net Worth




The estimated Net Worth of Mark B Skaletsky is at least $625 Thousand dollars as of 8 March 2007. Mark Skaletsky owns over 20,000 units of Immunogen stock worth over $624,800 and over the last 21 years Mark sold IMGN stock worth over $0.

Mark Skaletsky IMGN stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Immunogen stock since 2007, according to the Form 4 filled with the SEC. Most recently Mark exercised 20,000 units of IMGN stock worth $219,200 on 8 March 2007.

The largest trade Mark's ever made was exercising 20,000 units of Immunogen stock on 8 March 2007 worth over $219,200. On average, Mark trades about 800 units every 0 days since 2003. As of 8 March 2007 Mark still owns at least 20,000 units of Immunogen stock.

You can see the complete history of Mark Skaletsky stock trades at the bottom of the page.



What's Mark Skaletsky's mailing address?

Mark's mailing address filed with the SEC is , , , , .

Insiders trading at Immunogen

Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.



What does Immunogen do?

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.



What does Immunogen's logo look like?

Immunogen, Inc. logo

Complete history of Mark Skaletsky stock trades at Alkermes plc, AMAG Pharmaceuticals, and Immunogen

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
8 Mar 2007 AMAG AMAG Pharmaceuticals, Inc. Mark B Skaletsky
Director
 Option 20,000 $10.96 $219,200
8 Mar 2007
20,000 ↗


Immunogen executives and stock owners

Immunogen executives and other stock owners filed with the SEC include: